Celldex Q2 net loss $56.6M ($0.85/share); cash $630.3M; barzolvolimab shows durable complete response at 76 weeks

Celldex Therapeutics, Inc.

2025-Q2 EPS reported -$1.66 revenue$1,424,000

Net loss of $56.6M versus $35.8M in Q2 2024; R&D spend rose to $54.2M on barzolvolimab trials.
Cash and securities $630.3M (down $43M QoQ); company expects runway through 2027.
Phase 2 CSU barzolvolimab: up to 41% complete response at 76 weeks (7 months off-treatment); 48% no quality-of-life impact.
Phase 3 CSU program (EMBARQ-CSU1/2) enrolling globally; Phase 2 CIndU and EoE data due in 2H 2025.
Phase 1 CDX-622 (bispecific SCF/TSLP) in healthy volunteers: Part 1 data expected 2H 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.